The selectivity of the cancer cells to TIC10 and TRAIL-inducing compounds relies on the overexpression of DR4 and DR5 compared to non-cancerous cells [37,38]; thus, these compounds are promising targeted drugs. The gene discussed is TNFRSF10B; the disease is cancer.